Latest News and Press Releases

An Orphan Drug Designation Could Provide Significant Benefits to Regen SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC Pink: RGBP and RGBPP) today provides further insight...

Interim analysis shows misetionamide is very well tolerated in combination with gemcitabine; rates of confirmed response, stable disease, and progression-free survival compare favorably with...

Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Neuropathic Pain (Neuralgia) - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering. The comprehensive report...

Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering. This clinical trial report...

Company’s PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing...

Dublin, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The "Aplastic Anemia - Global Clinical Trials Review, 2024" report has been added to ResearchAndMarkets.com's offering.The clinical trial report provides...

HUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced the successful closing of the second...

HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced a $10 million equity financing with...

Pasithea Tx' PAS-004 Phase 1 trial advances to a 15mg dose after no toxicities or rash observed, highlighting its safety and differentiated profile.